Dianthus Therapeutics (DNTH) Competitors $23.48 +0.06 (+0.23%) As of 01:06 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DNTH vs. OGN, KNSA, IBRX, CNTA, ARWR, BLTE, RXRX, BHC, OCUL, and AGIOShould you be buying Dianthus Therapeutics stock or one of its competitors? The main competitors of Dianthus Therapeutics include Organon & Co. (OGN), Kiniksa Pharmaceuticals International (KNSA), ImmunityBio (IBRX), Centessa Pharmaceuticals (CNTA), Arrowhead Pharmaceuticals (ARWR), Belite Bio (BLTE), Recursion Pharmaceuticals (RXRX), Bausch Health Cos (BHC), Ocular Therapeutix (OCUL), and Agios Pharmaceuticals (AGIO). These companies are all part of the "pharmaceutical products" industry. Dianthus Therapeutics vs. Its Competitors Organon & Co. Kiniksa Pharmaceuticals International ImmunityBio Centessa Pharmaceuticals Arrowhead Pharmaceuticals Belite Bio Recursion Pharmaceuticals Bausch Health Cos Ocular Therapeutix Agios Pharmaceuticals Organon & Co. (NYSE:OGN) and Dianthus Therapeutics (NASDAQ:DNTH) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation and dividends. Which has higher earnings and valuation, OGN or DNTH? Organon & Co. has higher revenue and earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrganon & Co.$6.40B0.38$864M$2.693.46Dianthus Therapeutics$6.24M121.10-$84.97M-$3.25-7.22 Do insiders & institutionals believe in OGN or DNTH? 77.4% of Organon & Co. shares are held by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are held by institutional investors. 2.0% of Organon & Co. shares are held by insiders. Comparatively, 8.2% of Dianthus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more volatility & risk, OGN or DNTH? Organon & Co. has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500. Comparatively, Dianthus Therapeutics has a beta of 1.43, indicating that its share price is 43% more volatile than the S&P 500. Do analysts rate OGN or DNTH? Organon & Co. currently has a consensus price target of $18.00, indicating a potential upside of 93.24%. Dianthus Therapeutics has a consensus price target of $54.00, indicating a potential upside of 130.03%. Given Dianthus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Dianthus Therapeutics is more favorable than Organon & Co..Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organon & Co. 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.50Dianthus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is OGN or DNTH more profitable? Organon & Co. has a net margin of 11.15% compared to Dianthus Therapeutics' net margin of -2,364.56%. Organon & Co.'s return on equity of 163.88% beat Dianthus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Organon & Co.11.15% 163.88% 6.99% Dianthus Therapeutics -2,364.56%-34.72%-32.72% Does the media favor OGN or DNTH? In the previous week, Dianthus Therapeutics had 4 more articles in the media than Organon & Co.. MarketBeat recorded 10 mentions for Dianthus Therapeutics and 6 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 1.39 beat Dianthus Therapeutics' score of -0.24 indicating that Organon & Co. is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dianthus Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryOrganon & Co. beats Dianthus Therapeutics on 10 of the 17 factors compared between the two stocks. Get Dianthus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNTH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DNTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DNTH vs. The Competition Export to ExcelMetricDianthus TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$755.69M$3.11B$5.76B$9.54BDividend YieldN/A2.23%4.53%4.07%P/E Ratio-7.2220.5130.4425.06Price / Sales121.10235.81391.3087.06Price / CashN/A42.3737.0358.50Price / Book2.497.908.986.19Net Income-$84.97M-$54.72M$3.26B$265.38M7 Day Performance15.93%0.82%0.64%-1.44%1 Month Performance13.19%4.99%3.81%-1.01%1 Year Performance-17.72%8.46%28.11%18.66% Dianthus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DNTHDianthus Therapeutics1.0572 of 5 stars$23.48+0.2%$54.00+130.0%-19.2%$755.69M$6.24M-7.2280Analyst ForecastOGNOrganon & Co.4.7141 of 5 stars$9.00-2.4%$18.00+100.0%-54.9%$2.40B$6.40B3.354,000Positive NewsKNSAKiniksa Pharmaceuticals International2.4321 of 5 stars$32.74+1.8%$41.17+25.7%+26.1%$2.38B$423.24M818.70220Insider TradeIBRXImmunityBio2.2971 of 5 stars$2.47+1.2%$12.25+396.0%-43.1%$2.31B$14.74M-5.15590CNTACentessa Pharmaceuticals2.1794 of 5 stars$16.61-2.4%$28.10+69.2%+43.8%$2.27B$6.85M-9.18200Analyst RevisionARWRArrowhead Pharmaceuticals3.702 of 5 stars$17.21+4.8%$43.14+150.7%-14.4%$2.27B$3.55M-13.45400Analyst RevisionBLTEBelite Bio2.575 of 5 stars$69.50-0.5%$96.67+39.1%+27.9%$2.22BN/A-51.1010RXRXRecursion Pharmaceuticals2.5768 of 5 stars$5.29-1.3%$7.00+32.3%-33.4%$2.18B$58.84M-2.97400News CoverageInsider TradeBHCBausch Health Cos4.3097 of 5 stars$6.68+16.1%$9.00+34.8%+30.3%$2.13B$9.63B25.6820,700Positive NewsHigh Trading VolumeOCULOcular Therapeutix4.0539 of 5 stars$12.56+2.9%$17.20+36.9%+35.3%$2.12B$63.72M-9.81230AGIOAgios Pharmaceuticals4.2941 of 5 stars$35.10-1.8%$56.33+60.5%-17.9%$2.08B$36.50M3.19390 Related Companies and Tools Related Companies Organon & Co. Alternatives Kiniksa Pharmaceuticals International Alternatives ImmunityBio Alternatives Centessa Pharmaceuticals Alternatives Arrowhead Pharmaceuticals Alternatives Belite Bio Alternatives Recursion Pharmaceuticals Alternatives Bausch Health Cos Alternatives Ocular Therapeutix Alternatives Agios Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DNTH) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dianthus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dianthus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access